Fig. 3: Effects of LMs on microglial activation and amyloid burden.
a Immunohistochemical staining of brain sections of cortical and hippocampal areas from AppNL-G-F and wild-type (WT) mice using the microglia marker Iba1, showing higher numbers of Iba1-labelled microglia in AppNL-G-F mice than in both WT mice and AppNL-G-F mice treated with LMs. b Densitometry of the area covered by Iba1-positive microglia in WT-Veh, App NL-G-F-Veh and AppNL-G-F-LMs mice showing the differences seen in a. c Immunohistochemistry for APP and Thioflavin-S co-staining in the cerebral cortex and hippocampus from WT-Veh, AppNL-G-F-Veh and AppNL-G-F-LMs mice. d Comparison of the counts of diffuse and neuritic Aβ plaques in the cortex and hippocampus shows no difference between the AppNL-G-F-Veh and AppNL-G-F-LMs group. e Analysis of Aβ42 levels in formic acid extracts of cerebral cortex by Meso Scale did not show any effect of LM treatment in AppNL-G-F mice. Mann-Whitney U test was used for comparisons and correction was performed manually by multiplying with the number of comparisons. Data are presented as mean ± S.E.M (n = 5 mice/group). *P < 0.05, **P < 0.01, ***P < 0.001. Scale bars = 600 and 150 μm. Iba1 ionized calcium binding adaptor protein 1.
